Peaches Biotech Group appoints Alfonso Ortín as new PR Director
The incorporation comes in as the company launches important trials in the area of immunological oncology and regenerative tissue immunology.
Madrid, February 24, 2022.- Peaches Biotech Group, the Spanish company which specializes in the development of innovative treatments in regenerative medicine and advanced therapies, today announces the appointment of Alfonso Ortín as the new PR Director of the group, in order to accelerate the company's strategy of consolidation.
Alfonso Ortín began his experience as Director of the Mercedes Benz Spain Press Office and later directed, for 28 years, the PR department of Fiat Chrysler Automobiles Spain. For the last 5 years he has been Pharmamar's PR Director.
He joins the company at a time of significant growth and expansion where the dossier and the request for the trial of a treatment based, on PRS - Selective Rich Plasma -, to prevent the cytokine storm that will be tested in the first place, are being finalized now in patients with COVID-19. Furthermore, after the acquisition of the patent from Harvard (opT cells), for the "recollection and re-education of the T-cells" of the patient with pancreatic cancer and to be targeted against the tumor, it is expected to have the first preclinical results in the coming months, and it will be able to start the first trial with patients at the end of the year.
Milestones that will be followed by the expansion of newly advanced biological therapies, then applied to highly prevalent pathologies, thus placing Peaches Biotech on the international map of biomedical innovation.
This appointment represents the commitment to the growth and international expansion of Peaches Biotech Group.
Alfonso faces this new stage with enthusiasm. “The biotechnological sector is already exciting, but also joining a group that is betting on being a reference for research and development in advanced therapies gives me immense satisfaction in my professional career”, he commented.
For his part, Juan Carlos de Gregorio, CEO of the Peaches Biotech Group, explains: “We are delighted to welcome Alfonso Ortín. His career and professionalism in the field of communication make him a perfect ally for us. He joins the team at a time when we are launching several trials in the area of immunological oncology and advanced biological therapies. Ortín will play an important role in transmitting our investigative function and our commitment to society”.
For further information: